Literature DB >> 20021861

[Estimation of cancer incidence and mortality in China in 2004-2005].

Wan-qing Chen1.   

Abstract

OBJECTIVE: To estimate the cancer incidence and mortality in China in 2004 - 2005 based on available resources.
METHODS: The cancer mortality and incidence ratios were obtained on the basis of national cancer registration database in 2003 and 2004 adjusted by age and area. The crude cancer mortalities were retrieved from the database of the third national death survey 2004-2005. Incidence rates of specified cancer types were calculated using mortality and M/I ratios.
RESULTS: The total estimated cancer incidence and mortality per year in 2004 - 2005 were 2 596 112 new cases and 1 798 147 deaths, both were higher in males than in females. There were 1 337 227 new cases and 841 860 deaths in urban areas compared with 1 258 885 new cases and 956 287 deaths in rural areas. Cancers of the lung, stomach, liver, esophagus and colorectum/anus were the commonest cancers in China with 483 040, 428 380, 370 236, 236 589 and 197 873 new cases, respectively. Those five cancers were leading causes of cancer death with a number of 420 411, 339 308, 318 756, 190 233 and 101 684, respectively.
CONCLUSION: Cancer burden in China is getting more and more serious. It is imperative to enhance effective cancer prevention and control in China.

Entities:  

Mesh:

Year:  2009        PMID: 20021861

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  33 in total

1.  GSTM1 and GSTT1 polymorphisms and colorectal cancer risk in Chinese population: a meta-analysis.

Authors:  Dan Wang; Li-Mei Zhang; Jun-Xia Zhai; Dian-Wu Liu
Journal:  Int J Colorectal Dis       Date:  2012-01-13       Impact factor: 2.571

2.  A study of patients with brain metastases as the initial manifestation of their systemic cancer in a Chinese population.

Authors:  Jia Jin; Xinli Zhou; Xiaohua Liang; Ruofan Huang; Zhaohui Chu; Jingwei Jiang; Qiong Zhan
Journal:  J Neurooncol       Date:  2010-10-27       Impact factor: 4.130

3.  CRR9p polymorphism as a protective factor for lung cancer.

Authors:  Yang Chen; Zhiguo Yu; Bo Zhang; Zhengqi Chang; Hong Wang; Zhandi Liu
Journal:  Tumour Biol       Date:  2014-06-24

4.  X-ray repair cross-complementing group 1 Arg194Trp polymorphism is associated with increased risk of lung cancer in Chinese Han population.

Authors:  Tao Wu; Yun-hua Xu; Xiao-lei Ye
Journal:  Tumour Biol       Date:  2013-05-08

5.  Glutathione S-transferase M1 null genotype is associated with increased risk of oral cancer in East Asians: a meta-analysis.

Authors:  Yi Zhang; Qingqing Yu; Weixian Yu; Min Hu
Journal:  Tumour Biol       Date:  2013-06-26

6.  Expression of interleukin-17 and its clinical significance in gastric cancer patients.

Authors:  Xin Ying Meng; Chang Hong Zhou; Jian Ma; Chen Jiang; Ping Ji
Journal:  Med Oncol       Date:  2012-06-29       Impact factor: 3.064

7.  Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China.

Authors:  Tao Suo; Haile Mahteme; Xin-Yu Qin
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

8.  RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Authors:  Song Dong; Ai-Lin Guo; Zhi-Hong Chen; Zhen Wang; Xu-Chao Zhang; Ying Huang; Zhi Xie; Hong-Hong Yan; Hua Cheng; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2010-03-13       Impact factor: 17.388

9.  Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy.

Authors:  Li Li; Jia Ji; Jian-Bing Wang; Mayineur Niyazi; You-Lin Qiao; Paolo Boffetta
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

10.  Glutathione S-transferase T1 null genotype is associated with oral cancer susceptibility in Asian populations.

Authors:  Gang Dong; Yan Tian; Shulan Chen; Xin Xu; Jianjin Zheng; Tao Li
Journal:  Tumour Biol       Date:  2013-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.